Trial Title:
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
NCT ID:
NCT05554406
Condition:
Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Acute Myeloid Leukemia Post Cytotoxic Therapy
Acute Myeloid Leukemia, Myelodysplasia-Related
Conditions: Official terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Cytarabine
Azacitidine
Venetoclax
Daunorubicin
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Azacitidine
Description:
Given SC or IV
Arm group label:
Arm III (azacitidine, venetoclax)
Other name:
5 AZC
Other name:
5-AC
Other name:
5-Azacitidine
Other name:
5-Azacytidine
Other name:
5-AZC
Other name:
Azacytidine
Other name:
Azacytidine, 5-
Other name:
Ladakamycin
Other name:
Mylosar
Other name:
U-18496
Other name:
Vidaza
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo collection of blood
Arm group label:
Arm I (cytarabine, daunorubicin)
Arm group label:
Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
Arm III (azacitidine, venetoclax)
Arm group label:
Arm IV (daunorubicin and cytarabine liposome)
Arm group label:
Arm V (daunorubicin and cytarabine liposome, venetoclax)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Bone Marrow Aspiration
Description:
Undergo bone marrow aspiration
Arm group label:
Arm I (cytarabine, daunorubicin)
Arm group label:
Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
Arm IV (daunorubicin and cytarabine liposome)
Arm group label:
Arm V (daunorubicin and cytarabine liposome, venetoclax)
Intervention type:
Drug
Intervention name:
Cytarabine
Description:
Given IV
Arm group label:
Arm I (cytarabine, daunorubicin)
Arm group label:
Arm II (cytarabine, daunorubicin, venetoclax)
Other name:
.beta.-Cytosine arabinoside
Other name:
1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
Other name:
1-.beta.-D-Arabinofuranosylcytosine
Other name:
1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
Other name:
1-Beta-D-arabinofuranosylcytosine
Other name:
1.beta.-D-Arabinofuranosylcytosine
Other name:
2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
Other name:
2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
Other name:
Alexan
Other name:
Ara-C
Other name:
ARA-cell
Other name:
Arabine
Other name:
Arabinofuranosylcytosine
Other name:
Arabinosylcytosine
Other name:
Aracytidine
Other name:
Aracytin
Other name:
Aracytine
Other name:
Beta-Cytosine Arabinoside
Other name:
CHX-3311
Other name:
Cytarabinum
Other name:
Cytarbel
Other name:
Cytosar
Other name:
Cytosine Arabinoside
Other name:
Cytosine-.beta.-arabinoside
Other name:
Cytosine-beta-arabinoside
Other name:
Erpalfa
Other name:
Starasid
Other name:
Tarabine PFS
Other name:
U 19920
Other name:
U-19920
Other name:
Udicil
Other name:
WR-28453
Intervention type:
Drug
Intervention name:
Daunorubicin Hydrochloride
Description:
Given IV
Arm group label:
Arm I (cytarabine, daunorubicin)
Arm group label:
Arm II (cytarabine, daunorubicin, venetoclax)
Other name:
Cerubidin
Other name:
Cerubidine
Other name:
Cloridrato de Daunorubicina
Other name:
Daunoblastin
Other name:
Daunoblastina
Other name:
Daunoblastine
Other name:
Daunomycin Hydrochloride
Other name:
Daunomycin, hydrochloride
Other name:
Daunorubicin.HCl
Other name:
Daunorubicini Hydrochloridum
Other name:
FI-6339
Other name:
Ondena
Other name:
RP-13057
Other name:
Rubidomycin Hydrochloride
Other name:
Rubilem
Intervention type:
Procedure
Intervention name:
Echocardiography
Description:
Undergo ECHO
Arm group label:
Arm I (cytarabine, daunorubicin)
Arm group label:
Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
Arm III (azacitidine, venetoclax)
Arm group label:
Arm IV (daunorubicin and cytarabine liposome)
Arm group label:
Arm V (daunorubicin and cytarabine liposome, venetoclax)
Other name:
EC
Intervention type:
Drug
Intervention name:
Liposome-encapsulated Daunorubicin-Cytarabine
Description:
Given IV
Arm group label:
Arm IV (daunorubicin and cytarabine liposome)
Arm group label:
Arm V (daunorubicin and cytarabine liposome, venetoclax)
Other name:
CPX 351
Other name:
CPX-351
Other name:
CPX351
Other name:
Cytarabine and Daunorubicin Liposomal
Other name:
Cytarabine-Daunorubicin Liposome for Injection
Other name:
Daunorubicin and Cytarabine (Liposomal)
Other name:
Liposomal AraC-Daunorubicin CPX-351
Other name:
Liposomal Cytarabine-Daunorubicin
Other name:
Liposome-encapsulated Combination of Daunorubicin and Cytarabine
Other name:
Vyxeos
Intervention type:
Procedure
Intervention name:
Multigated Acquisition Scan
Description:
Undergo MUGA
Arm group label:
Arm I (cytarabine, daunorubicin)
Arm group label:
Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
Arm III (azacitidine, venetoclax)
Arm group label:
Arm IV (daunorubicin and cytarabine liposome)
Arm group label:
Arm V (daunorubicin and cytarabine liposome, venetoclax)
Other name:
Blood Pool Scan
Other name:
Equilibrium Radionuclide Angiography
Other name:
Gated Blood Pool Imaging
Other name:
Gated Heart Pool Scan
Other name:
MUGA
Other name:
MUGA Scan
Other name:
Multi-Gated Acquisition Scan
Other name:
Radionuclide Ventriculogram Scan
Other name:
Radionuclide Ventriculography
Other name:
RNV Scan
Other name:
RNVG
Other name:
SYMA Scanning
Other name:
Synchronized Multigated Acquisition Scanning
Intervention type:
Drug
Intervention name:
Venetoclax
Description:
Given PO
Arm group label:
Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
Arm III (azacitidine, venetoclax)
Arm group label:
Arm V (daunorubicin and cytarabine liposome, venetoclax)
Other name:
ABT 199
Other name:
ABT-0199
Other name:
ABT-199
Other name:
ABT199
Other name:
GDC 0199
Other name:
GDC-0199
Other name:
GDC0199
Other name:
RG7601
Other name:
Venclexta
Other name:
Venclyxto
Summary:
This phase II MyeloMATCH treatment trial tests whether the standard approach of
cytarabine and daunorubicin in comparison to the following experimental regimens works to
shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin
and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3)
azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax.
"High-risk" refers to traits that have been known to make the AML harder to treat.
Cytarabine is in a class of medications called antimetabolites. It works by slowing or
stopping the growth of cancer cells in the body. Daunorubicin is in a class of
medications called anthracyclines. It also works by slowing or stopping the growth of
cancer cells in the body. Azacitidine is in a class of medications called demethylation
agents. It works by helping the bone marrow to produce normal blood cells and by killing
abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2)
inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed
for cancer cell survival. There is evidence that these newer experimental treatment
regimens may work better in getting rid of more AML compared to the standard approach of
cytarabine and daunorubicin.
Detailed description:
PRIMARY OBJECTIVE:
I. To compare measurable residual disease (MRD) negative complete remission (CR) rates
between each of the experimental regimens and cytarabine + daunorubicin (7+3).
SECONDARY OBJECTIVES:
I. To estimate the frequency and severity of toxicities with each of the regimens.
II. To estimate complete remission (CR) rates, complete remission with incomplete count
recovery (CRi, with and without MRD) rates, event-free survival (EFS), time to relapse,
relapse-free survival (RFS), and overall survival (OS) with each of the regimens.
III. To describe and compare MRD negative CR rates by genomic subgroups within and across
randomized arms.
BAKING OBJECTIVE:
I. To bank specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 5 arms.
ARM I: Patients receive cytarabine intravenously (IV) continuously on days 1-7 and
daunorubicin IV on days 1-3 per standard approach of each cycle. Cycles repeat every 28
days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients
may receive an additional cycle of cytarabine IV continuously on days 1-5 and
daunorubicin IV on days 1-2. Patients undergo echocardiography (ECHO) or multigated
acquisition (MUGA) scan during screening. Patients also undergo a bone marrow aspiration
and collection of blood throughout the trial.
ARM II: Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on
days 2-4 with venetoclax orally (PO) on days 1-11 of each cycle. Cycles repeat every 28
days for 1 cycle in the absence of disease progression or unacceptable toxicity. Patients
may receive an additional cycle of cytarabine IV continuously on days 2-6 and
daunorubicin IV on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA
scan during screening. Patients also undergo a bone marrow aspiration and collection of
blood throughout the trial.
ARM III: Patients receive azacitidine subcutaneously (SC) or IV on days 1-7 and
venetoclax PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2 cycles in the
absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA
scan during screening. Patients also undergo a bone marrow aspiration and collection of
blood throughout the trial.
ARM IV: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days
1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of
disease progression or unacceptable toxicity. Patients may receive an additional cycle of
daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo
ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and
collection of blood throughout the trial.
ARM V: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days
1, 3, and 5 and venetoclax PO on days 1-14 of each cycle. Cycles repeat every 28 days for
1 cycle in the absence of disease progression or unacceptable toxicity. Patients may
receive an additional cycle of daunorubicin and cytarabine liposome IV over 90 minutes on
days 1 and 3 and venetoclax PO on days 1-7. Patients undergo ECHO or MUGA scan during
screening. Patients also undergo a bone marrow aspiration and collection of blood
throughout the trial.
After completion of study treatment, patients follow up every month for first year, every
2 months for the second year, every 3 months for the third year and every 6 months to
year 5.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- STEP 1 REGISTRATION:
- Participants must have been registered to Master Screening and Re-Assessment
Protocol, MYELOMATCH, prior to consenting to this study. Participants must have been
assigned to this clinical trial, via MATCHBox, prior to registration to this study.
- Note: Pre-enrollment/diagnosis labs must have already been performed under the
MYELOMATCH
- Participants must have newly diagnosed, untreated acute myeloid leukemia (AML) per
World Health Organization (WHO) criteria
- Participants must have high-risk (adverse) AML per European LeukemiaNet (ELN) 2017
criteria
- Participants with therapy-related AML (t-AML), or with AML evolving from an
antecedent hematologic disorder (such as myeloproliferative neoplasm), or AML with
myelodysplasia-related changes (AML-MRC) are eligible
- Acute promyelocytic leukemia is excluded
- Participants with favorable or intermediate risk disease are excluded
- Participants with FLT3 mutations (ITD or TKD) are excluded
- Participants with t(9;22) translocation are excluded
- A single dose of intrathecal chemotherapy is allowed prior to study entry
- Prior anthracycline therapy is allowed but must not exceed a cumulative lifetime
dose of 200 mg/m^2 daunorubicin or equivalent. Prior hypomethylating agent (HMA)
exposure is allowed, as long as not for AML diagnosis
- Participants must not have received or be currently receiving any prior therapy for
acute myeloid leukemia. Hydroxyurea to control the white blood cells (WBC) is
allowed prior to registration and initiation of protocol-defined therapy. All trans
retinoic acid (ATRA) given until a diagnosis of acute promyelocytic leukemia is
ruled out is also allowed.
- Participants must not be receiving or planning to receive any other investigational
agents before completing protocol therapy
- Participants must be between 18 and 59 years of age
- Participants must have Zubrod performance status =< 3 as determined by a history and
physical (H&P) completed within 14 days prior to registration
- Participants must have a complete medical history and physical exam within 7 days
prior to registration
- Participants must be able to swallow and retain oral medications and have no known
gastrointestinal disorders likely to interfere with absorption of oral medications
- Participants with known human immunodeficiency virus (HIV)-infection must be on
effective anti-retroviral therapy at time of registration and have undetectable HIV
viral load within 6 months prior to registration
- Participants with evidence of chronic hepatitis B virus (HBV) infection must have
undetectable HBV viral load within 28 days prior to registration and be on
suppressive therapy, if indicated
- Participants with a history of hepatitis C virus (HCV) infection must have been
treated and cured. Participants with active HCV infection who are currently on
treatment must have an undetectable HCV viral load within 28 days prior to
registration
- The following tests must be performed within 14 days prior to registration to
establish baseline values:
- Complete blood count (CBC)/differential/platelets
- Total bilirubin
- Lactate dehydrogenase (LDH)
- Albumin
- Glucose
- Fibrinogen
- Participants must have adequate kidney function as evidenced by creatinine clearance
>= 30mL/min (by Cockcroft Gault) within 28 days prior to registration
- Participants must have adequate liver function as evidenced by aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x upper limit of
normal (ULN), and total bilirubin =< 2.0 x ULN (or 5.0 x ULN if the participant has
a history of Gilbert's disease) within 28 days prior to registration
- Total bilirubin =< 2.0 x ULN (or 5.0 x ULN if the participant has a history of
Gilbert's disease) within 28 days prior to registration
- Participants must have adequate cardiac function as determined by echocardiography
or MUGA scan with an ejection fraction >= 50% within 28 days prior to registration
- Participants with a prior or concurrent malignancy whose natural history (in the
opinion of the treating physician) does not have the potential to interfere with the
safety or efficacy assessment of the investigational regimen are eligible for this
trial. No concurrent therapies for such malignancy are allowed with the exception of
hormonal therapy
- Participants with known history of Wilson's disease or other known copper-metabolism
disorder are excluded
- Participants must not be pregnant or nursing. Women/men of reproductive potential
must have agreed to use 2 contraception methods. A woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months. In addition to routine contraceptive methods (e.g., hormonal
contraceptives [examples include birth control pills, vaginal rings, or patches]
associated with inhibition of ovulation for at least 1 month prior to taking study
drug), "effective contraception" also includes heterosexual celibacy and surgery
intended to prevent pregnancy (or with a side-effect of pregnancy prevention)
defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation.
However, if at any point a previously celibate participant chooses to become
heterosexually active during the time period for use of contraceptive measures
outlined in the protocol, he/she is responsible for beginning contraceptive
measures. A barrier method should be used during this study along with hormonal
contraceptives from initial study drug administration to 30 days after the last dose
of study drug as drug-drug interaction with venetoclax is unknown
- Participants must have agreed to have specimens submitted for translational medicine
(MRD) under the myeloMATCH MSRP and specimens must be submitted
- Participants must be informed of the investigational nature of this study and must
sign and give informed consent in accordance with institutional and federal
guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has
been entered in the system
Gender:
All
Minimum age:
18 Years
Maximum age:
59 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Banner University Medical Center - Tucson
Address:
City:
Tucson
Zip:
85719
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
UACC-IIT@uacc.arizona.edu
Investigator:
Last name:
Sharad Khurana
Email:
Principal Investigator
Facility:
Name:
University of Arizona Cancer Center-North Campus
Address:
City:
Tucson
Zip:
85719
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
UACC-IIT@uacc.arizona.edu
Investigator:
Last name:
Sharad Khurana
Email:
Principal Investigator
Facility:
Name:
Cedars Sinai Medical Center
Address:
City:
Los Angeles
Zip:
90048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
310-423-8965
Investigator:
Last name:
Noah M. Merin
Email:
Principal Investigator
Facility:
Name:
Augusta University Medical Center
Address:
City:
Augusta
Zip:
30912
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
706-721-2388
Email:
ga_cares@augusta.edu
Investigator:
Last name:
Vamsi Kota
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
OSF Saint Joseph Medical Center
Address:
City:
Bloomington
Zip:
61701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Bloomington
Address:
City:
Bloomington
Zip:
61704
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Canton
Address:
City:
Canton
Zip:
61520
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Carthage
Address:
City:
Carthage
Zip:
62321
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern University
Address:
City:
Chicago
Zip:
60611
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1301
Email:
cancer@northwestern.edu
Investigator:
Last name:
Yasmin Abaza
Email:
Principal Investigator
Facility:
Name:
University of Chicago Comprehensive Cancer Center
Address:
City:
Chicago
Zip:
60637
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Olatoyosi M. Odenike
Email:
Principal Investigator
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Decatur Memorial Hospital
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Dixon
Address:
City:
Dixon
Zip:
61021
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
815-285-7800
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Eureka
Address:
City:
Eureka
Zip:
61530
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Galesburg
Address:
City:
Galesburg
Zip:
61401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Kewanee Clinic
Address:
City:
Kewanee
Zip:
61443
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Macomb
Address:
City:
Macomb
Zip:
61455
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Ottawa Clinic
Address:
City:
Ottawa
Zip:
61350
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Pekin
Address:
City:
Pekin
Zip:
61554
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peoria
Address:
City:
Peoria
Zip:
61615
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Methodist Medical Center of Illinois
Address:
City:
Peoria
Zip:
61636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
OSF Saint Francis Medical Center
Address:
City:
Peoria
Zip:
61637
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peru
Address:
City:
Peru
Zip:
61354
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Princeton
Address:
City:
Princeton
Zip:
61356
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-545-7929
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-444-7541
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Memorial Hospital
Address:
City:
Springfield
Zip:
62781
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-528-7541
Email:
pallante.beth@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare - Washington
Address:
City:
Washington
Zip:
61571
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
University of Kansas Clinical Research Center
Address:
City:
Fairway
Zip:
66205
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Cancer Center
Address:
City:
Kansas City
Zip:
66160
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Hospital-Indian Creek Campus
Address:
City:
Overland Park
Zip:
66211
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Hospital-Westwood Cancer Center
Address:
City:
Westwood
Zip:
66205
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
The James Graham Brown Cancer Center at University of Louisville
Address:
City:
Louisville
Zip:
40202
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
502-562-3429
Investigator:
Last name:
Mohamed M. Hegazi
Email:
Principal Investigator
Facility:
Name:
UofL Health Medical Center Northeast
Address:
City:
Louisville
Zip:
40245
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
502-852-2755
Email:
ctoinfo@louisville.edu
Investigator:
Last name:
Mohamed M. Hegazi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Wayne State University/Karmanos Cancer Institute
Address:
City:
Detroit
Zip:
48201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-576-9790
Email:
ctoadmin@karmanos.org
Investigator:
Last name:
Vijendra Singh
Email:
Principal Investigator
Facility:
Name:
Weisberg Cancer Treatment Center
Address:
City:
Farmington Hills
Zip:
48334
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-576-9790
Email:
ctoadmin@karmanos.org
Investigator:
Last name:
Vijendra Singh
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Address:
City:
Columbus
Zip:
39705
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Cancer Center-Grenada
Address:
City:
Grenada
Zip:
38901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Union County
Address:
City:
New Albany
Zip:
38652
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Oxford
Address:
City:
Oxford
Zip:
38655
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Desoto
Address:
City:
Southhaven
Zip:
38671
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at West County Hospital
Address:
City:
Creve Coeur
Zip:
63141
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Ramzi Abboud
Email:
Principal Investigator
Facility:
Name:
Washington University School of Medicine
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Ramzi Abboud
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center-South County
Address:
City:
Saint Louis
Zip:
63129
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Ramzi Abboud
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Christian Hospital
Address:
City:
Saint Louis
Zip:
63136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Ramzi Abboud
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Saint Peters Hospital
Address:
City:
Saint Peters
Zip:
63376
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Ramzi Abboud
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Logan Health Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Bellevue
Address:
City:
Bellevue
Zip:
68123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Michael Haddadin
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Village Pointe
Address:
City:
Omaha
Zip:
68118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-5600
Investigator:
Last name:
Michael Haddadin
Email:
Principal Investigator
Facility:
Name:
University of Nebraska Medical Center
Address:
City:
Omaha
Zip:
68198
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Michael Haddadin
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
University of New Mexico Cancer Center
Address:
City:
Albuquerque
Zip:
87106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
505-925-0348
Email:
HSC-ClinicalTrialInfo@salud.unm.edu
Investigator:
Last name:
Charles Foucar
Email:
Principal Investigator
Facility:
Name:
Montefiore Medical Center - Moses Campus
Address:
City:
Bronx
Zip:
10467
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
718-379-6866
Email:
eskwak@montefiore.org
Investigator:
Last name:
Ioannis Mantzaris
Email:
Principal Investigator
Facility:
Name:
University of Rochester
Address:
City:
Rochester
Zip:
14642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
585-275-5830
Investigator:
Last name:
Paul M. Barr
Email:
Principal Investigator
Facility:
Name:
State University of New York Upstate Medical University
Address:
City:
Syracuse
Zip:
13210
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
315-464-5476
Investigator:
Last name:
Teresa C. Gentile
Email:
Principal Investigator
Facility:
Name:
Duke University Medical Center
Address:
City:
Durham
Zip:
27710
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
888-275-3853
Investigator:
Last name:
Harry P. Erba
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Manu Pandey
Email:
Principal Investigator
Facility:
Name:
Oregon Health and Science University
Address:
City:
Portland
Zip:
97239
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-494-1080
Email:
trials@ohsu.edu
Investigator:
Last name:
Curtis A. Lachowiez
Email:
Principal Investigator
Facility:
Name:
Reading Hospital
Address:
City:
West Reading
Zip:
19611
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
610-988-9323
Investigator:
Last name:
Terrence P. Cescon
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Spartanburg
Address:
City:
Boiling Springs
Zip:
29316
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Easley
Address:
City:
Easley
Zip:
29640
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-522-2066
Email:
Kim.Williams3@prismahealth.org
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Butternut
Address:
City:
Greenville
Zip:
29605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Faris
Address:
City:
Greenville
Zip:
29605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Eastside
Address:
City:
Greenville
Zip:
29615
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Greer
Address:
City:
Greer
Zip:
29650
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Seneca
Address:
City:
Seneca
Zip:
29672
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Collierville
Address:
City:
Collierville
Zip:
38017
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Memphis
Address:
City:
Memphis
Zip:
38120
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
University of Virginia Cancer Center
Address:
City:
Charlottesville
Zip:
22908
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
434-243-6303
Email:
uvacancertrials@hscmail.mcc.virginia.edu
Investigator:
Last name:
Daniel R. Reed
Email:
Principal Investigator
Facility:
Name:
Gundersen Lutheran Medical Center
Address:
City:
La Crosse
Zip:
54601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
608-775-2385
Email:
cancerctr@gundersenhealth.org
Investigator:
Last name:
David E. Marinier
Email:
Principal Investigator
Facility:
Name:
Centro Comprensivo de Cancer de UPR
Address:
City:
San Juan
Zip:
00927
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
888-823-5923
Email:
ctsucontact@westat.com
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Facility:
Name:
San Juan City Hospital
Address:
City:
San Juan
Zip:
00936
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
787-763-1296
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Start date:
September 25, 2024
Completion date:
March 31, 2027
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05554406
